Impedimed (ASX:IPD)is also up again this week, rising 25%, after recent good news. IPD Q3 FY23 results were in line with expectations, while the big catalyst for the company was the US National Comprehensive Cancer Network (NCCN) including bioimpedance spectroscopy (BIS) as part of its new version of guidelines.
The inclusion of BIS in the NCCN guidelines will help establish BIS as standard of care, and will accelerate adoption by US private payors and providers.
IPD is the only FDA approved provider of BIS which meets the guidelines.
“I think last week’s news from the quarterly around payor response has begun to sink in a little, and spurred on by some small but handy director buying,” Wilkie said.
CEO and MD Richard Valencia ponied up for ~$52k of IPD stock on market on April 20, while non-executive chairman Donald Williams purchased ~$17,500 worth of stock on April 27.
Furthermore, Wilkie said it seems the market are showing they are willing to back health stocks over a sustained period more than just on release of positive news.
IPD Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
